Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC-TB-DILI trial
TCTR20260312003Phase 3Not yet recruiting
- Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of acetylcysteine in Tuberculosis (TB), Drug-induced hepatitis (DILI), sponsored by Ratchadaphiseksomphot Endowment Fund. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
Tuberculosis (TB)Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on TCTR20260312003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260312003.